Please select the option that best describes you:
Do you offer local treatment to the breast primary in patients with de novo oligometastatic hormone positive breast cancer?
How has your practice been impacted by the ECOG 2108 (Khan et al. ASCO 2020 Abst LBA2)? Are there sites or distribution of disease that prompt you to treat?
Answer from: Medical Oncologist at Academic Institution
The E2108 study by Khan et al., showed that early local therapy in de-novo metastatic BC did not improve PFS/OS, and in fact showed worse OS in the small subset of TNBC in the study (20 patients). Although there was improved locoregional control in the local therapy arm, there was no quality of life...
Sign in or Register to read more